godfather of surgery

Chapter 1281 Another Boomerang
The closed-door meeting between several pharmaceutical giants in Switzerland, Europe, is still ongoing, and they have not yet reached an agreement.

"He betrayed us! Utterly and completely!" The CEO of a French giant waved his tablet, which displayed Rigauyan's pale and humiliated face at the press conference. "BG not only defected, but also openly admitted to leading in those high-risk technologies! All our previous public opinion guidance has become a joke!"

“It’s not just a joke, it’s a disaster!” A bald German slammed his fist on the table. “Stock price! Look at our stock price! In just three days, our company’s average market value has evaporated by more than 15 percent! You’re not doing much better. Investors are panic selling. They’re worried that we’ll be overthrown in the future.”

"Why would Rikoyan do this? Is he crazy? Or is he really terrified by the illness?" some people questioned.

“I’ve received inside information,” a director from Switzerland said in a low voice, instantly silencing everyone. “Rolf, the shadow of Li Gaoyang, has secretly assembled a negotiation team and flown to China. The target is clear—Huang Jiacai, president of Ruixing Medical. They’re not going to protest, they’re going to beg for cooperation, or rather, to surrender, to negotiate a less ugly surrender agreement.”

Silence, a deathly silence.

The once highly respected president, an American with gold-rimmed glasses, slowly surveyed the room, his voice hoarse but carrying an undeniable resolve: "Ladies and gentlemen, we've been arguing like this for days, cursing Li Gaoyang for days, repeating the same things for days. Arguing and complaining are pointless. Li Gaoyang has taught us all a lesson with his own health and the future of BG—Professor Yang's technology is not a paper tiger bluffing. Blockades and smears are utterly fragile in the face of absolute technological superiority and the will to survive."

He stood up, placed his hands on the table, and leaned forward: "The fact is, the treatment concepts represented by K-therapy and X-2 technology may indeed be a generation ahead of our current best solutions. Li Gaoyang isn't stupid; he's voting with his life. Now, we only have two paths before us: First, continue to stubbornly resist and watch helplessly as BG and Ruixing reach an exclusive or priority agreement, and then they join forces to bulldoze our market share built up over decades; second—"

He took a deep breath: "Put aside arrogance and prejudice, acknowledge reality, take the initiative to reach out, and seek cooperation, even if it's costly. We must get our ticket, even if it's just standing room only. Otherwise, it's uncertain how many companies will be left in this room ten years from now. We must have a strong sense of crisis."

The room was completely silent, save for heavy breathing. Everyone understood that this was the cruelest, most realistic judgment. Self-interest is the eternal driving force, and at this moment it had overwhelmed all ideological barriers and the arrogance of technological fundamentalism.

"I agree to contact them." Finally, someone spoke with difficulty.

"Seconded."

"I second that... but we must stand together. We cannot allow Huang Jiacai to defeat them one by one, nor can we allow BG Group to get there first."

"Immediately assemble a top-level joint negotiation delegation and contact Ruixing, the sooner the better."

After several days of debate, a resolution was quickly reached. A carefully worded but clearly humble invitation to cooperate was urgently sent to the headquarters of Ruixing Group through encrypted channels.

……

Almost simultaneously, in China, Southern Metropolis Daily.

The curved conference room on the top floor of the Ruixing Group headquarters.

Huang Jiacai sat in the main seat, not wearing a suit, but a finely made dark gray Zhongshan suit, the top button meticulously fastened. In front of him lay a printed copy of the invitation letter that had just arrived, and beside it, a thick stack of assessment reports on BG Group's core assets, patent portfolio, and global distribution network.

He read very slowly, his index finger occasionally idly stroking the edge of the paper report.

Rolf sat at the other end of the long table, with his four core advisors behind him. His back was straight, and his knuckles were slightly white as he placed them under the table. He didn't urge them, but waited quietly.

Finally, Huang Jiacai put down his report, took off his glasses, and slowly wiped the lenses with a soft cloth. In fact, Huang Jiacai was not nearsighted; his glasses were plano lenses. He wore glasses only to create a refined image.

He didn't look at Rolf; his gaze seemed to be fixed on a point in the void.

“Mr. Rolf,” Huang Jiacai began, his voice calm and devoid of any emotional fluctuation, “we have seen BG’s sincerity. We have also heard Mr. Rigoyang’s personal statement at the press conference.”

He put his glasses back on, his gaze finally settling on Rolf's face, calm and composed: "However, business collaborations, especially global collaborations involving the licensing of groundbreaking technologies, cannot be based solely on personal health concerns or temporary, unavoidable public statements. They require a more solid foundation, a clearer structure, and an exchange of value that is equal or even surpasses that of others."

Rolf's heart sank slightly, but he maintained a polite smile: "Of course, Mr. Huang. We have come with the utmost sincerity. BG is willing to play the most active partner role in the global promotion of K-therapy and X-2 technology. Our top-notch network across Europe and America, mature approval expedited channels, and strong market and insurance payment system influence can clear many obstacles for the popularization of these two technologies. This is a win-win situation."

“Win-win…” Huang Jiacai repeated the word softly, a very faint smile appearing at the corners of his mouth, fleeting in an instant. He leaned back slightly.

“Mr. Rolf, you are an outstanding strategist. You should be well aware that K-therapy and X-2 are not just two technologies. They represent a new medical model that is emerging.” Huang Jiacai’s tone remained calm, but every word seemed to have been precisely crafted. “This model is not swayed by the interests of any single country or group. Its core driving force is to solve the suffering caused by diseases that humanity has not yet conquered; it is about universal benefit.”

He paused, his gaze sweeping over the staff behind Rolf.

"Therefore, regarding cooperation, Ruixing has a basic, and ultimately final, stance." Huang Jiacai's voice echoed clearly in the conference room, "We will not sign any exclusive agreements with any single group that would lead to the fragmentation of the global market. This applies to BG and other companies that are currently extending invitations."

Rolf's pupils contracted sharply, and the expressions of his aides behind him changed slightly. This wasn't the exorbitant demand followed by a negotiated settlement they had anticipated; it was a declaration that fundamentally overturned the rules of the game.

Huang Jiacai seemed oblivious to their reaction and continued, "Regarding K-therapy and X-2 technology, Ruixing will soon collaborate with the Sanbo Research Institute to announce a globally unified technology licensing and access framework. This framework will be based on clear efficacy data, transparent cost accounting, and most importantly, set tiered, affordable licensing fees and drug pricing policies according to the per capita GDP and healthcare payment capacity of different countries and regions."

He leaned forward slightly, and a sharp glint finally appeared in his usually calm eyes: "Our goal is to get these truly effective treatments to every patient in need as quickly and equitably as possible, not to make them a new tool for a few interest groups to reap excessive profits and create medical inequality." He tapped his fingertips lightly on the table, his voice sounding a little stronger this time.

"Gentlemen," Huang Jiacai's gaze returned to Rolf's somewhat stiff face, his tone even carrying a hint of regret, "So, what we are discussing here today is not whether BG can obtain exclusivity or priority rights, that is impossible. What we can discuss is how BG can, within this inclusive global framework, leverage your existing channels and capabilities to strive to become one of the first, or in some regions, the most efficient cooperative promotion partners."

Rolf felt his throat go dry. He had imagined countless difficult negotiation scenarios, a tit-for-tat tug-of-war over terms, and was even prepared to cede core interests. But he never expected that Huang Jiacai would simply overturn the table and redefine the rules of the entire game.

This is not negotiation; this is a notification, a universal ultimatum from a technological leader to the old order.

“Mr. Huang…” Rolf struggled to organize his thoughts, “Your vision is very grand, but the business reality is complex, with regulations, payment systems, market competition in various places… and as researchers of new drugs and therapies, what you need is to recoup your costs and make a profit as quickly as possible, and we can help you do that.”

“You’re right, that’s why we need experienced partners like BG to handle these complex issues,” Huang Jiacai replied, his tone still calm. “But the premise of cooperation is that we agree on this basic framework. Otherwise, Ruixing doesn’t mind relying on itself or finding other like-minded partners to move forward slowly.” He glanced at the report on the table. “In terms of time, we have enough patience.”

Huang Jiacai wasn't just thinking about making a quick buck this time; he wanted to leverage BG Group and other giants to expand his network globally.

Rolf closed his eyes. He now understood that Huang Jiacai was more shrewd and farsighted than he had imagined. What he wanted was to use the power of BG Group to expand its global network, and BG had no choice but to do so.

The initial press conference by Li Gaoyang was merely a prelude, a prelude to the current strategic layout. Now, BG Group is in a dilemma: if it cooperates, it will benefit others; if it refuses to cooperate, other multinational corporations will certainly step in, and BG Group will lose its first-mover advantage in this new field.

A few seconds later, Rolf opened his eyes, his gaze now calm and collected. "I need to speak with Mr. Rigoyan and the board of directors."

"Please go ahead," Huang Jiacai said calmly. "However, several other companies are expected to arrive tomorrow. The evaluation window we are giving all potential partners is limited, and I hope your sincerity will not be wasted."

“I understand!” Rolf’s forehead was covered in fine beads of sweat. None of the plans he had prepared before the negotiation could be used. Huang Jiacai was completely unpredictable.

The negotiations were called off, and Rolf and his men hurriedly left, their figures appearing somewhat rushed.

Huang Jiacai remained alone in the conference room, picked up the invitation letters from the other major companies again, glanced at them, and casually put them aside.

……

The conference room of the Sanbo Research Institute.

On a huge, high-definition electronic screen, Li Gaoyang's full-body real-time 3D image is slowly rotating, with countless translucent light bands representing nerve bundles, vascular networks, and lymphatic circulation interwoven to form a complex and intricate life map. The image is magnified and finally focuses on the depths of the brain, the brainstem, and surrounding areas.

Yang Ping stood in front of the screen, his brows slightly furrowed. He wore specially made glasses, his fingers tracing patterns in the air, manipulating the image to peel away layers, color it, and highlight it. This was a three-dimensional virtual reality image constructed using the digital medical laboratory of Nandu Medical University.

“Here,” his finger stopped at an abnormal signal at the back of the brainstem that was almost integrated with normal tissue, “the recurrent tumor has formed extensive adhesions to the surrounding tissue and is showing obvious infiltrative growth. It is no longer suitable for surgery. He missed the best time for surgery. Now we can only consider K therapy. Whether K therapy is effective for this type of tumor is currently unknown. It is worth a try, but there are many obstacles to using K therapy.”

His voice was exceptionally clear, and Song Ziming, Xu Zhiliang, and others watched intently. Johannesson, as the chief expert of Li Gaoyang's medical advisory group, also attended the case discussion.

obstacle?

Johannesson knew that if Professor Yang said the surgery was not possible, then no doctor in the world could perform it. But what was the obstacle that Professor Yang mentioned?

"What obstacles exist?" Johannesson asked directly.

Song Ziming continued Yang Ping's explanation: "Our K therapy is not currently on the market. According to our own experimental rules, we must obtain clinical trial approval in the country before we can accept citizens of that country as volunteers. We have had painful lessons regarding such cross-border clinical trials before. We once accepted a British patient as a clinical volunteer, and although he agreed, for various reasons, it ultimately caused strong negative social commentary in Europe, and even his family members became one of the promoters of this negative commentary. Therefore, we have become more cautious about clinical trials and have formulated new rules: only citizens of the country in which clinical trials are approved can become volunteers."

Johannesson knew what had happened before; these so-called boomerangs of negative public opinion had now hit Rikoyan, who was actually one of the promoters of the negative public opinion at the time.

If that were the case, Rikoyan probably wouldn't have been able to accept K therapy, because at the time, there were many obstacles, and K therapy had never obtained clinical trial approval in the United States.

If surgery and K therapy are not an option, then there's nothing that can be done.

Johannesson was momentarily speechless. Asking them to change the experimental rules was impossible! As Dr. Song had just said, these were protective rules learned from painful lessons, and they couldn't be changed for anyone, especially not Li Gaoyang.

It seems that the only thing we can do is focus on getting K therapy approved for clinical trials in the United States.

With the power of the Li Gaoyang family, it wouldn't be difficult for K therapy to obtain clinical approval in the United States, Johannesson thought.